Login to Your Account



Concert, Avanir Make Sweet Music in Potential $200M Deal

By Marie Powers
Staff Writer

Thursday, March 1, 2012
Privately held Concert Pharmaceuticals Inc. increased its bandwidth by signing an exclusive licensing agreement with Avanir Pharmaceuticals Inc. for the global rights to develop and commercialize multiple deuterium-modified dextromethorphan (d-DM) compounds developed by Concert for neurological and psychiatric disorders, as well as certain rights to additional unspecified d-DM compounds.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription